1. From the Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California-San Francisco/Mt. Zion Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California, and TAP Pharmaceutical Products, Inc., Lake Forest, Illinois